{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:56:41Z","timestamp":1794059801950,"version":"4.8.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG059716"],"award-info":[{"award-number":["R01-AG059716"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01-AG049164)"],"award-info":[{"award-number":["K01-AG049164)"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG061518"],"award-info":[{"award-number":["R01-AG061518"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer\u2019s is complex, with numerous environmental and genetic factors contributing to the disease. Late-onset AD is highly heritable (60 to 80%), and over 40 risk loci for AD have been identified via large genome-wide association studies, most of which are common variants with small effect sizes. Although these discoveries have provided novel insight on biological contributors to AD, disease-modifying treatments remain elusive. Recently, the concepts of resistance to pathology and resilience against the downstream consequences of pathology have been of particular interest in the Alzheimer\u2019s field as studies continue to identify individuals who evade the pathology of the disease even into late life and individuals who have all of the neuropathological features of AD but evade downstream neurodegeneration and cognitive impairment. It has been hypothesized that a shift in focus from Alzheimer\u2019s risk to resilience presents an opportunity to uncover novel biological mechanisms of AD and to identify promising therapeutic targets for the disease. This review will highlight a selection of genes and variants that have been reported to confer protection from AD within the literature and will also discuss evidence for the biological underpinnings behind their protective effect with a focus on genes involved in lipid metabolism, cellular trafficking, endosomal and lysosomal function, synaptic function, and inflammation. Finally, we offer some recommendations in areas where the field can rapidly advance towards precision interventions that leverage the ideas of protection and resilience for the development of novel therapeutic strategies.<\/jats:p>","DOI":"10.1186\/s13024-021-00452-5","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T16:02:28Z","timestamp":1619712148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Protective genes and pathways in Alzheimer\u2019s disease: moving towards precision interventions"],"prefix":"10.1186","volume":"16","author":[{"given":"Mabel","family":"Seto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3377-7014","authenticated-orcid":false,"given":"Timothy J.","family":"Hohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16:391\u2013460. https:\/\/doi.org\/10.1002\/alz.12068.","DOI":"10.1002\/alz.12068"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119.","journal-title":"Lancet Neurol"},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris LM, Yu C-E, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213\u201327.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"452_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000512","volume":"6","author":"C Reitz","year":"2020","unstructured":"Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease. Neurol Genet. 2020;6:e512.","journal-title":"Neurol Genet"},{"key":"452_CR6","first-page":"14","volume":"25","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019;25:14\u201333.","journal-title":"Continuum (Minneap Minn)"},{"key":"452_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031039","volume":"7","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, Chakraverty S, Mayo K, Vallania FLM, Mitra RD, Faber K, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One. 2012;7:e31039.","journal-title":"PLoS One"},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/mp.2012.15","volume":"17","author":"C Pottier","year":"2012","unstructured":"Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry. 2012;17:875\u20139.","journal-title":"Mol Psychiatry"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2017.08.013","volume":"14","author":"C Cruchaga","year":"2018","unstructured":"Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, et al. Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement. 2018;14:205\u201314.","journal-title":"Alzheimers Dement"},{"key":"452_CR10","doi-asserted-by":"crossref","unstructured":"Baker E, Escott-Price V. Polygenic risk scores in Alzheimer's disease: current applications and future directions. Front Digit Health. 2020;2:14.","DOI":"10.3389\/fdgth.2020.00014"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/ana.24999","volume":"82","author":"V Escott-Price","year":"2017","unstructured":"Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann Neurol. 2017;82:311\u20134.","journal-title":"Ann Neurol"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1093\/brain\/awv268","volume":"138","author":"V Escott-Price","year":"2015","unstructured":"Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain. 2015;138:3673\u201384.","journal-title":"Brain"},{"key":"452_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002258","volume":"14","author":"RS Desikan","year":"2017","unstructured":"Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med. 2017;14:e1002258.","journal-title":"PLoS Med"},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3233\/JAD-150749","volume":"53","author":"V Chouraki","year":"2016","unstructured":"Chouraki V, Reitz C, Maury F, Bis JC, Bellenguez C, Yu L, et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer's disease. J Alzheimers Dis. 2016;53:921\u201332.","journal-title":"J Alzheimers Dis"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","volume":"63","author":"M Gatz","year":"2006","unstructured":"Gatz M, Reynolds CA, Fratiglioni L. Role of genes and environments for explaining alzheimer disease. Arch Gen Psychiatry. 2006;63:168\u201374.","journal-title":"Arch Gen Psychiatry"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51:414\u201330.","journal-title":"Nat Genet"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452\u20138.","journal-title":"Nat Genet"},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet. 2019;51:404\u201313.","journal-title":"Nat Genet"},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/cts.12491","volume":"11","author":"J Cummings","year":"2018","unstructured":"Cummings J. Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci. 2018;11:147\u201352.","journal-title":"Clin Transl Sci"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.","journal-title":"Alzheimers Res Ther"},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg4017","volume":"16","author":"AR Harper","year":"2015","unstructured":"Harper AR, Nayee S, Topol EJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet. 2015;16:689\u2013701.","journal-title":"Nat Rev Genet"},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-019-0479-y","volume":"11","author":"TJ Montine","year":"2019","unstructured":"Montine TJ, Cholerton BA, Corrada MM, Edland SD, Flanagan ME, Hemmy LS, et al. Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimers Res Ther. 2019;11:22.","journal-title":"Alzheimers Res Ther"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40142-019-0156-2","volume":"7","author":"SJ Andrews","year":"2019","unstructured":"Andrews SJ, Fulton-Howard B, Goate A. Protective variants in Alzheimer\u2019s disease. Curr Genet Med Rep. 2019;7:1\u201312.","journal-title":"Curr Genet Med Rep"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"MVF Silva","year":"2019","unstructured":"Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MG. Alzheimer\u2019s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:33.","journal-title":"J Biomed Sci"},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1212\/WNL.0000000000003397","volume":"87","author":"TJ Hohman","year":"2016","unstructured":"Hohman TJ, McLaren DG, Mormino EC, Gifford KA, Libon DJ, Jefferson AL. Asymptomatic Alzheimer disease: defining resilience. Neurology. 2016;87:2443\u201350.","journal-title":"Neurology"},{"key":"452_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/156720511795745348","volume":"8","author":"I Driscoll","year":"2011","unstructured":"Driscoll I, Troncoso J. Asymptomatic Alzheimers disease: a Prodrome or a state of resilience? Curr Alzheimer Res. 2011;8:330\u20135.","journal-title":"Curr Alzheimer Res"},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6:82.","journal-title":"Alzheimers Res Ther"},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/archneurol.2011.157","volume":"68","author":"JA Sonnen","year":"2011","unstructured":"Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, et al. Ecology of the aging human brain. Arch Neurol. 2011;68:1049\u201356.","journal-title":"Arch Neurol"},{"key":"452_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1086\/500615","volume":"78","author":"IK Kotowski","year":"2006","unstructured":"Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78:410\u201322.","journal-title":"Am J Hum Genet"},{"key":"452_CR30","unstructured":"PCSK9-inhibitor drug class that grew out of UTSW research becomes a game-changer for patient with extremely high cholesterol. https:\/\/www.utsouthwestern.edu\/newsroom\/articles\/year-2016\/pcsk9-patient-khera.html. Accessed 1 Sept 2020."},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"1510.e1519","DOI":"10.1016\/j.neurobiolaging.2013.12.010","volume":"35","author":"BA Benitez","year":"2014","unstructured":"Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging. 2014;35:1510.e1519\u20131510.e1511.5100000000000001E5100000000000026.","journal-title":"Neurobiol Aging"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017;49:1373\u201384.","journal-title":"Nat Genet"},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, Lopera F, O\u2019Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680\u20133.","journal-title":"Nat Med"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0197-4580(02)00094-5","volume":"24","author":"MA Wollmer","year":"2003","unstructured":"Wollmer MA, Streffer JR, L\u00fctjohann D, Tsolaki M, Iakovidou V, Hegi T, et al. Bergmann Kv, Nitsch RM, et al: ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer\u2019s disease. Neurobiol Aging. 2003;24:421\u20136.","journal-title":"Neurobiol Aging"},{"key":"452_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1212\/WNL.0000000000005303","volume":"90","author":"EM Arenaza-Urquijo","year":"2018","unstructured":"Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90:695\u2013703.","journal-title":"Neurology"},{"key":"452_CR36","volume":"2","author":"SL Andersen","year":"2020","unstructured":"Andersen SL. Centenarians as models of resistance and resilience to Alzheimer\u2019s disease and related dementias. Adv Geriatr Med Res. 2020;2:e200018.","journal-title":"Adv Geriatr Med Res"},{"key":"452_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","volume":"11","author":"Y Stern","year":"2012","unstructured":"Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11:1006\u201312.","journal-title":"Lancet Neurol"},{"key":"452_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/WAD.0b013e318211c83c","volume":"25","author":"ES Sharp","year":"2011","unstructured":"Sharp ES, Gatz M. Relationship between education and dementia: an updated systematic review. Alzheimer Dis Assoc Disord. 2011;25:289\u2013304.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"452_CR39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1017\/S1355617702813248","volume":"8","author":"Y Stern","year":"2002","unstructured":"Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8:448\u201360.","journal-title":"J Int Neuropsychol Soc"},{"key":"452_CR40","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jalz.2018.07.219","volume":"16","author":"Y Stern","year":"2020","unstructured":"Stern Y, Arenaza-Urquijo EM, Bartr\u00e9s-Faz D, Belleville S, Cantilon M, Chetelat G, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020;16:1305\u201311.","journal-title":"Alzheimers Dement"},{"key":"452_CR41","doi-asserted-by":"publisher","first-page":"108091","DOI":"10.1016\/j.celrep.2020.108091","volume":"32","author":"AR Ouellette","year":"2020","unstructured":"Ouellette AR, Neuner SM, Dumitrescu L, Anderson LC, Gatti DM, Mahoney ER, et al. Cross-species analyses identify Dlgap2 as a regulator of age-related cognitive decline and Alzheimer's dementia. Cell Rep. 2020;32:108091.","journal-title":"Cell Rep"},{"key":"452_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96\u20139.","journal-title":"Nature"},{"key":"452_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180\u20134.","journal-title":"Nat Genet"},{"key":"452_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaneurol.2020.0414","volume":"77","author":"ME Belloy","year":"2020","unstructured":"Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Initiative ftAsDN: Association of Klotho-VS Heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol. 2020;77:849\u201362.","journal-title":"JAMA Neurol"},{"key":"452_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12864-016-2725-z","volume":"17","author":"KL Ayers","year":"2016","unstructured":"Ayers KL, Mirshahi UL, Wardeh AH, Murray MF, Hao K, Glicksberg BS, et al. A loss of function variant in CASP7 protects against Alzheimer\u2019s disease in homozygous APOE \u03b54 allele carriers. BMC Genomics. 2016;17:445.","journal-title":"BMC Genomics"},{"key":"452_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neulet.2017.11.027","volume":"664","author":"\u00c1 Feh\u00e9r","year":"2018","unstructured":"Feh\u00e9r \u00c1, Giricz Z, Juh\u00e1sz A, P\u00e1k\u00e1ski M, Janka Z, K\u00e1lm\u00e1n J. ABCA1 rs2230805 and rs2230806 common gene variants are associated with Alzheimer's disease. Neurosci Lett. 2018;664:79\u201383.","journal-title":"Neurosci Lett"},{"key":"452_CR47","doi-asserted-by":"publisher","first-page":"235.e231","DOI":"10.1016\/j.neurobiolaging.2016.04.004","volume":"46","author":"C Sassi","year":"2016","unstructured":"Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, et al. ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiol Aging. 2016;46:235.e231\u2013235.e2359.","journal-title":"Neurobiol Aging"},{"key":"452_CR48","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s12035-016-9780-y","volume":"54","author":"C-C Zhang","year":"2017","unstructured":"Zhang C-C, Wang H-F, Tan M-S, Wan Y, Zhang W, Zheng Z-J, et al. SORL1 is associated with the risk of late-onset Alzheimer\u2019s disease: a replication study and meta-analyses. Mol Neurobiol. 2017;54:1725\u201332.","journal-title":"Mol Neurobiol"},{"key":"452_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13073-017-0486-1","volume":"9","author":"PG Ridge","year":"2017","unstructured":"Ridge PG, Karch CM, Hsu S, Arano I, Teerlink CC, Ebbert MTW, et al. Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. Genome Med. 2017;9:100.","journal-title":"Genome Med"},{"key":"452_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12017-017-8444-z","volume":"19","author":"CB Santos-Rebou\u00e7as","year":"2017","unstructured":"Santos-Rebou\u00e7as CB, Gon\u00e7alves AP, dos Santos JM, Abdala BB, Motta LB, Laks J, et al. Pimentel MMG: rs3851179 polymorphism at 5\u2032 to the PICALM gene is associated with Alzheimer and Parkinson diseases in Brazilian population. NeuroMolecular Med. 2017;19:293\u20139.","journal-title":"NeuroMolecular Med"},{"key":"452_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ana.24349","volume":"77","author":"K Nho","year":"2015","unstructured":"Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, et al. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015;77:547\u201352.","journal-title":"Ann Neurol"},{"key":"452_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00401-019-02066-0","volume":"139","author":"Z Li","year":"2020","unstructured":"Li Z, Farias FHG, Dube U, Del-Aguila JL, Mihindukulasuriya KA, Fernandez MV, et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139:45\u201361.","journal-title":"Acta Neuropathol"},{"key":"452_CR53","doi-asserted-by":"publisher","first-page":"217.e217","DOI":"10.1016\/j.neurobiolaging.2016.03.009","volume":"42","author":"M Ghani","year":"2016","unstructured":"Ghani M, Sato C, Kakhki EG, Gibbs JR, Traynor B, St George-Hyslop P, et al. Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set. Neurobiol Aging. 2016;42:217.e217\u20133.","journal-title":"Neurobiol Aging"},{"key":"452_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamaneurol.2013.4781","volume":"71","author":"G Weinstein","year":"2014","unstructured":"Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D, et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham heart study. JAMA Neurol. 2014;71:55\u201361.","journal-title":"JAMA Neurol"},{"key":"452_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1196\/annals.1297.005","volume":"1019","author":"EH Corder","year":"2004","unstructured":"Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004;1019:24\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"452_CR56","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2174\/1567205016666190805165607","volume":"16","author":"FF Zeng","year":"2019","unstructured":"Zeng FF, Liu J, He H, Gao XP, Liao MQ, Yu XX, et al. Association of PICALM gene polymorphisms with Alzheimer's disease: evidence from an updated meta-analysis. Curr Alzheimer Res. 2019;16:1196\u2013205.","journal-title":"Curr Alzheimer Res"},{"key":"452_CR57","doi-asserted-by":"crossref","unstructured":"Masri I, Salami A, El Shamieh S. Bissar-Tadmouri N. rs3851179G>A in PICALM is protective against Alzheimer's disease in five different countries surrounding the Mediterranean. Curr Aging Sci. 2019;13:162\u201368.","DOI":"10.2174\/1874609812666191019143237"},{"key":"452_CR58","unstructured":"APP. https:\/\/www.alzforum.org\/mutations\/app. Accessed 1 Apr 2021."},{"key":"452_CR59","doi-asserted-by":"publisher","first-page":"30977","DOI":"10.1074\/jbc.M114.599027","volume":"289","author":"I Benilova","year":"2014","unstructured":"Benilova I, Gallardo R, Ungureanu AA, Castillo Cano V, Snellinx A, Ramakers M, et al. The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-\u03b2 (A\u03b2) aggregation. J Biol Chem. 2014;289:30977\u201389.","journal-title":"J Biol Chem"},{"key":"452_CR60","doi-asserted-by":"publisher","first-page":"30990","DOI":"10.1074\/jbc.M114.589069","volume":"289","author":"JA Maloney","year":"2014","unstructured":"Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014;289:30990\u20131000.","journal-title":"J Biol Chem"},{"key":"452_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ana.24969","volume":"82","author":"H Martiskainen","year":"2017","unstructured":"Martiskainen H, Herukka S-K, Stan\u010d\u00e1kov\u00e1 A, Paananen J, Soininen H, Kuusisto J, et al. Decreased plasma \u03b2-amyloid in the Alzheimer's disease APP A673T variant carriers. Ann Neurol. 2017;82:128\u201332.","journal-title":"Ann Neurol"},{"key":"452_CR62","doi-asserted-by":"publisher","first-page":"2909.e2901","DOI":"10.1016\/j.neurobiolaging.2015.07.011","volume":"36","author":"J Mengel-From","year":"2015","unstructured":"Mengel-From J, Jeune B, Pentti T, McGue M, Christensen K, Christiansen L. The APP A673T frequency differs between Nordic countries. Neurobiol Aging. 2015;36:2909.e2901\u20134.","journal-title":"Neurobiol Aging"},{"key":"452_CR63","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaneurol.2014.2157","volume":"72","author":"L-S Wang","year":"2015","unstructured":"Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol. 2015;72:209\u201316.","journal-title":"JAMA Neurol"},{"issue":"35","key":"452_CR64","first-page":"e1715","volume":"2014","author":"MN Bamne","year":"1779","unstructured":"Bamne MN, Demirci FY, Berman S, Snitz BE, Rosenthal SL, Wang X, et al. Investigation of an amyloid precursor protein protective mutation (A673T) in a north American case-control sample of late-onset Alzheimer's disease. Neurobiol Aging. 1779;2014(35):e1715\u201376.","journal-title":"Neurobiol Aging"},{"key":"452_CR65","doi-asserted-by":"publisher","first-page":"935.e911","DOI":"10.1016\/j.neurobiolaging.2013.09.023","volume":"35","author":"YW Liu","year":"2014","unstructured":"Liu YW, He YH, Zhang YX, Cai WW, Yang LQ, Xu LY, et al. Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. Neurobiol Aging. 2014;35:935.e911\u201332.","journal-title":"Neurobiol Aging"},{"key":"452_CR66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"452_CR67","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science"},{"key":"452_CR68","doi-asserted-by":"crossref","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467\u201372.","DOI":"10.1212\/WNL.43.8.1467"},{"key":"452_CR69","doi-asserted-by":"crossref","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977\u201381.","DOI":"10.1073\/pnas.90.5.1977"},{"key":"452_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med. 2019;17:64.","journal-title":"BMC Med"},{"key":"452_CR71","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.","journal-title":"Nat Commun"},{"key":"452_CR72","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4103\/1673-5374.179044","volume":"11","author":"L Wu","year":"2016","unstructured":"Wu L, Zhao L. ApoE2 and Alzheimer's disease: time to take a closer look. Neural Regen Res. 2016;11:412\u20133.","journal-title":"Neural Regen Res"},{"key":"452_CR73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-020-00413-4","volume":"15","author":"Z Li","year":"2020","unstructured":"Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:63.","journal-title":"Mol Neurodegener"},{"key":"452_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","volume":"83","author":"N Zhao","year":"2018","unstructured":"Zhao N, Liu C-C, Qiao W, Bu G. Apolipoprotein E, receptors, and modulation of Alzheimer's disease. Biol Psychiatry. 2018;83:347\u201357.","journal-title":"Biol Psychiatry"},{"key":"452_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-016-0099-y","volume":"11","author":"Y Fu","year":"2016","unstructured":"Fu Y, Zhao J, Atagi Y, Nielsen HM, Liu C-C, Zheng H, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-\u03b2 uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener. 2016;11:37.","journal-title":"Mol Neurodegener"},{"key":"452_CR76","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of Apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 2020;77:470\u20139.","journal-title":"JAMA Neurol"},{"key":"452_CR77","doi-asserted-by":"publisher","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, et al. APOE\u03b54 potentiates the relationship between amyloid-\u03b2 and tau pathologies. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-0688-6. Online ahead of print.","DOI":"10.1038\/s41380-020-0688-6"},{"key":"452_CR78","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523\u20137.","journal-title":"Nature"},{"key":"452_CR79","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki Y, Painter MM, Bu G, Kanekiyo T. Apolipoprotein E as a therapeutic target in Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30:773\u201389.","journal-title":"CNS Drugs"},{"key":"452_CR80","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501\u201318.","journal-title":"Nat Rev Neurol"},{"key":"452_CR81","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/ejhg.2008.202","volume":"17","author":"P Henneman","year":"2009","unstructured":"Henneman P, van der Sman-de Beer F, Moghaddam PH, Huijts P, Stalenhoef AFH, Kastelein JJP, et al. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes. Eur J Hum Genet. 2009;17:620\u20138.","journal-title":"Eur J Hum Genet"},{"key":"452_CR82","doi-asserted-by":"publisher","first-page":"104809","DOI":"10.1016\/j.nbd.2020.104809","volume":"138","author":"AB Mart\u00ednez-Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez-Mart\u00ednez AB, Torres-Perez E, Devanney N, Del Moral R, Johnson LA, Arbones-Mainar JM. Beyond the CNS: the many peripheral roles of APOE. Neurobiol Dis. 2020;138:104809.","journal-title":"Neurobiol Dis"},{"key":"452_CR83","doi-asserted-by":"publisher","first-page":"134306","DOI":"10.1016\/j.neulet.2019.134306","volume":"708","author":"D Chernick","year":"2019","unstructured":"Chernick D, Ortiz-Valle S, Jeong A, Qu W, Li L. Peripheral versus central nervous system APOE in Alzheimer's disease: interplay across the blood-brain barrier. Neurosci Lett. 2019;708:134306.","journal-title":"Neurosci Lett"},{"key":"452_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","volume":"15","author":"T Williams","year":"2020","unstructured":"Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:8.","journal-title":"Mol Neurodegener"},{"key":"452_CR85","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/gepi.0164","volume":"22","author":"DC Ewbank","year":"2002","unstructured":"Ewbank DC. Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol. 2002;22:146\u201355.","journal-title":"Genet Epidemiol"},{"key":"452_CR86","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.jalz.2019.05.011","volume":"15","author":"AJ Huq","year":"2019","unstructured":"Huq AJ, Fransquet P, Laws SM, Ryan J, Sebra R, Masters CL, et al. Genetic resilience to Alzheimer's disease in APOE \u03b54 homozygotes: a systematic review. Alzheimers Dement. 2019;15:1612\u201323.","journal-title":"Alzheimers Dement"},{"key":"452_CR87","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1073\/pnas.022484299","volume":"99","author":"DE Arking","year":"2002","unstructured":"Arking DE, Krebsova A, Macek M Sr, Macek M Jr, Arking A, Mian IS, et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A. 2002;99:856\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"452_CR88","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.neurobiolaging.2018.12.014","volume":"76","author":"T Porter","year":"2019","unstructured":"Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, et al. Klotho allele status is not associated with A\u03b2 and APOE \u03b54-related cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2019;76:162\u20135.","journal-title":"Neurobiol Aging"},{"key":"452_CR89","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neurobiolaging.2017.02.019","volume":"55","author":"CF de Vries","year":"2017","unstructured":"de Vries CF, Staff RT, Harris SE, Chapko D, Williams DS, Reichert P, et al. Klotho, APOE\u03b54, cognitive ability, brain size, atrophy, and survival: a study in the Aberdeen birth cohort of 1936. Neurobiol Aging. 2017;55:91\u20138.","journal-title":"Neurobiol Aging"},{"key":"452_CR90","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.celrep.2014.03.076","volume":"7","author":"DB Dubal","year":"2014","unstructured":"Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, et al. Life extension factor klotho enhances cognition. Cell Rep. 2014;7:1065\u201376.","journal-title":"Cell Rep"},{"key":"452_CR91","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/acn3.161","volume":"2","author":"JS Yokoyama","year":"2015","unstructured":"Yokoyama JS, Sturm VE, Bonham LW, Klein E, Arfanakis K, Yu L, et al. Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann Clin Transl Neurol. 2015;2:215\u201330.","journal-title":"Ann Clin Transl Neurol"},{"key":"452_CR92","doi-asserted-by":"publisher","first-page":"e1878","DOI":"10.1212\/WNL.0000000000007323","volume":"92","author":"CM Erickson","year":"2019","unstructured":"Erickson CM, Schultz SA, Oh JM, Darst BF, Ma Y, Norton D, et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology. 2019;92:e1878\u201389.","journal-title":"Neurology"},{"key":"452_CR93","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jamaneurol.2020.0112","volume":"77","author":"DB Dubal","year":"2020","unstructured":"Dubal DB, Yokoyama JS. Longevity gene KLOTHO and Alzheimer disease\u2014a better fate for individuals who carry APOE \u03b54. JAMA Neurol. 2020;77:798\u2013800.","journal-title":"JAMA Neurol"},{"key":"452_CR94","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09687688.2013.837518","volume":"30","author":"M D\u00ebrmaku-Sopjani","year":"2013","unstructured":"D\u00ebrmaku-Sopjani M, Kolgeci S, Abazi S, Sopjani M. Significance of the anti-aging protein Klotho. Mol Membr Biol. 2013;30:369\u201385.","journal-title":"Mol Membr Biol"},{"key":"452_CR95","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1126\/science.1112766","volume":"309","author":"H Kurosu","year":"2005","unstructured":"Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829\u201333.","journal-title":"Science"},{"key":"452_CR96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbi.2019.03.007","volume":"80","author":"EJ Wolf","year":"2019","unstructured":"Wolf EJ, Morrison FG, Sullivan DR, Logue MW, Guetta RE, Stone A, et al. The goddess who spins the thread of life: Klotho, psychiatric stress, and accelerated aging. Brain Behav Immun. 2019;80:193\u2013203.","journal-title":"Brain Behav Immun"},{"key":"452_CR97","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/gerona\/gly261","volume":"74","author":"M Ullah","year":"2019","unstructured":"Ullah M, Sun Z. Klotho deficiency accelerates stem cells aging by impairing telomerase activity. J Gerontol A Biol Sci Med Sci. 2019;74:1396\u2013407.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"452_CR98","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fnagi.2017.00353","volume":"9","author":"X Kuang","year":"2017","unstructured":"Kuang X, Zhou HJ, Thorne AH, Chen XN, Li LJ, Du JR. Neuroprotective effect of Ligustilide through induction of \u03b1-Secretase processing of both APP and Klotho in a mouse model of Alzheimer's disease. Front Aging Neurosci. 2017;9:353.","journal-title":"Front Aging Neurosci"},{"key":"452_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neurobiolaging.2019.02.003","volume":"78","author":"CY Zeng","year":"2019","unstructured":"Zeng CY, Yang TT, Zhou HJ, Zhao Y, Kuang X, Duan W, et al. Lentiviral vector-mediated overexpression of Klotho in the brain improves Alzheimer's disease-like pathology and cognitive deficits in mice. Neurobiol Aging. 2019;78:18\u201328.","journal-title":"Neurobiol Aging"},{"key":"452_CR100","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-151101","volume":"51","author":"S Simonovitch","year":"2016","unstructured":"Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman DM, et al. Impaired autophagy in APOE4 astrocytes. J Alzheimers Dis. 2016;51:915\u201327.","journal-title":"J Alzheimers Dis"},{"key":"452_CR101","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jalz.2017.07.754","volume":"14","author":"PA Parcon","year":"2018","unstructured":"Parcon PA, Balasubramaniam M, Ayyadevara S, Jones RA, Liu L, Shmookler Reis RJ, et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers Dement. 2018;14:230\u201342.","journal-title":"Alzheimers Dement"},{"key":"452_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13239","volume":"19","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zeng C-Y, Li X-H, Yang T-T, Kuang X, Du J-R. Klotho overexpression improves amyloid-\u03b2 clearance and cognition in the APP\/PS1 mouse model of Alzheimer's disease. Aging Cell. 2020;19:e13239.","journal-title":"Aging Cell"},{"key":"452_CR103","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nature09788","volume":"472","author":"MA Burguillos","year":"2011","unstructured":"Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011;472:319\u201324.","journal-title":"Nature"},{"key":"452_CR104","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnen\/60.9.829","volume":"60","author":"KA Roth","year":"2001","unstructured":"Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J Neuropathol Exp Neurol. 2001;60:829\u201338.","journal-title":"J Neuropathol Exp Neurol"},{"key":"452_CR105","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12974-020-01902-5","volume":"17","author":"BA McKenzie","year":"2020","unstructured":"McKenzie BA, Fernandes JP, Doan MAL, Schmitt LM, Branton WG, Power C. Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis. J Neuroinflammation. 2020;17:253.","journal-title":"J Neuroinflammation"},{"key":"452_CR106","first-page":"108","volume":"2","author":"TT Rohn","year":"2009","unstructured":"Rohn TT, Head E. Caspases as therapeutic targets in Alzheimer's disease: is it time to \"cut\" to the chase? Int J Clin Exp Pathol. 2009;2:108\u201318.","journal-title":"Int J Clin Exp Pathol"},{"key":"452_CR107","doi-asserted-by":"publisher","first-page":"38029","DOI":"10.1074\/jbc.M509039200","volume":"280","author":"M Yamamoto","year":"2005","unstructured":"Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005;280:38029\u201334.","journal-title":"J Biol Chem"},{"key":"452_CR108","doi-asserted-by":"crossref","unstructured":"Chew H, Solomon VA, Fonteh AN. Involvement of lipids in Alzheimer\u2019s disease pathology and potential therapies. Front Physiol. 2020;11:598.","DOI":"10.3389\/fphys.2020.00598"},{"key":"452_CR109","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jalz.2015.04.006","volume":"11","author":"LT Nordestgaard","year":"2015","unstructured":"Nordestgaard LT, Tybj\u00e6rg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease. Alzheimers Dement. 2015;11:1430\u20138.","journal-title":"Alzheimers Dement"},{"key":"452_CR110","first-page":"824","volume":"2010","author":"R Koldamova","year":"1801","unstructured":"Koldamova R, Fitz NF, Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta. 1801;2010:824\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"452_CR111","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00401-019-01994-1","volume":"138","author":"A De Roeck","year":"2019","unstructured":"De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer's disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019;138:201\u201320.","journal-title":"Acta Neuropathol"},{"key":"452_CR112","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00401-016-1615-4","volume":"132","author":"OM Andersen","year":"2016","unstructured":"Andersen OM, Rudolph I-M, Willnow TE. Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease. Acta Neuropathol. 2016;132:653\u201365.","journal-title":"Acta Neuropathol"},{"key":"452_CR113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fphys.2013.00045","volume":"4","author":"A Elali","year":"2013","unstructured":"Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front Physiol. 2013;4:45.","journal-title":"Front Physiol"},{"key":"452_CR114","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1523\/JNEUROSCI.1937-12.2012","volume":"32","author":"NF Fitz","year":"2012","unstructured":"Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, et al. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci. 2012;32:13125\u201336.","journal-title":"J Neurosci"},{"key":"452_CR115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/brainsci8020027","volume":"8","author":"T Aikawa","year":"2018","unstructured":"Aikawa T, Holm M-L, Kanekiyo T. ABCA7 and pathogenic pathways of Alzheimer's disease. Brain Sci. 2018;8:27.","journal-title":"Brain Sci"},{"key":"452_CR116","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JAD-160456","volume":"54","author":"Y Fu","year":"2016","unstructured":"Fu Y, Hsiao JH, Paxinos G, Halliday GM, Kim WS. ABCA7 mediates phagocytic clearance of amyloid-\u03b2 in the brain. J Alzheimers Dis. 2016;54:569\u201384.","journal-title":"J Alzheimers Dis"},{"key":"452_CR117","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1523\/JNEUROSCI.3757-15.2016","volume":"36","author":"N Sakae","year":"2016","unstructured":"Sakae N, Liu CC, Shinohara M, Frisch-Daiello J, Ma L, Yamazaki Y, et al. ABCA7 deficiency accelerates amyloid-\u03b2 generation and Alzheimer's neuronal pathology. J Neurosci. 2016;36:3848\u201359.","journal-title":"J Neurosci"},{"key":"452_CR118","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1523\/JNEUROSCI.4165-12.2013","volume":"33","author":"WS Kim","year":"2013","unstructured":"Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, et al. Deletion of Abca7 increases cerebral amyloid-\u03b2 accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci. 2013;33:4387\u201394.","journal-title":"J Neurosci"},{"key":"452_CR119","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/hq0901.094500","volume":"21","author":"K Taira","year":"2001","unstructured":"Taira K, Bujo H, Hirayama S, Yamazaki H, Kanaki T, Takahashi K, et al. LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol. 2001;21:1501\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"452_CR120","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12035-014-8742-5","volume":"51","author":"RH Yin","year":"2015","unstructured":"Yin RH, Yu JT, Tan L. The role of SORL1 in Alzheimer's disease. Mol Neurobiol. 2015;51:909\u201318.","journal-title":"Mol Neurobiol"},{"key":"452_CR121","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00401-016-1566-9","volume":"132","author":"J Verheijen","year":"2016","unstructured":"Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Llad\u00f3 A, et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer\u2019s disease. Acta Neuropathol. 2016;132:213\u201324.","journal-title":"Acta Neuropathol"},{"key":"452_CR122","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ejhg.2017.87","volume":"25","author":"H Holstege","year":"2017","unstructured":"Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JGJ, Weiss M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer\u2019s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017;25:973\u201381.","journal-title":"Eur J Hum Genet"},{"key":"452_CR123","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.24305","volume":"77","author":"BN Vardarajan","year":"2015","unstructured":"Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol. 2015;77:215\u201327.","journal-title":"Ann Neurol"},{"key":"452_CR124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neulet.2008.05.049","volume":"440","author":"H K\u00f6lsch","year":"2008","unstructured":"K\u00f6lsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, et al. Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett. 2008;440:68\u201371.","journal-title":"Neurosci Lett"},{"key":"452_CR125","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000332017","volume":"32","author":"P Alexopoulos","year":"2011","unstructured":"Alexopoulos P, Guo L-H, Kratzer M, Westerteicher C, Kurz A, Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement Geriatr Cogn Disord. 2011;32:164\u201370.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"452_CR126","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","volume":"34","author":"DR Riddell","year":"2007","unstructured":"Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621\u20138.","journal-title":"Mol Cell Neurosci"},{"key":"452_CR127","doi-asserted-by":"publisher","first-page":"34144","DOI":"10.1074\/jbc.M110.108100","volume":"285","author":"JJ Donkin","year":"2010","unstructured":"Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein\/presenilin 1 mice. J Biol Chem. 2010;285:34144\u201354.","journal-title":"J Biol Chem"},{"key":"452_CR128","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12915-017-0432-0","volume":"15","author":"CJ Stefan","year":"2017","unstructured":"Stefan CJ, Trimble WS, Grinstein S, Drin G, Reinisch K, De Camilli P, et al. Membrane dynamics and organelle biogenesis\u2014lipid pipelines and vesicular carriers. BMC Biol. 2017;15:102.","journal-title":"BMC Biol"},{"key":"452_CR129","doi-asserted-by":"publisher","first-page":"616","DOI":"10.4103\/1673-5374.230276","volume":"13","author":"J Marsh","year":"2018","unstructured":"Marsh J, Alifragis P. Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen Res. 2018;13:616\u201323.","journal-title":"Neural Regen Res"},{"key":"452_CR130","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-019-0323-7","volume":"14","author":"ZP Van Acker","year":"2019","unstructured":"Van Acker ZP, Bretou M, Annaert W. Endo-lysosomal dysregulations and late-onset Alzheimer\u2019s disease: impact of genetic risk factors. Mol Neurodegener. 2019;14:20.","journal-title":"Mol Neurodegener"},{"key":"452_CR131","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s12035-018-1106-9","volume":"56","author":"NB Ma\u00f1ucat-Tan","year":"2019","unstructured":"Ma\u00f1ucat-Tan NB, Saadipour K, Wang YJ, Bobrovskaya L, Zhou XF. Cellular trafficking of amyloid precursor protein in Amyloidogenesis physiological and pathological significance. Mol Neurobiol. 2019;56:812\u201330.","journal-title":"Mol Neurobiol"},{"key":"452_CR132","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1567205012666141218140953","volume":"12","author":"RJ Baranello","year":"2015","unstructured":"Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res. 2015;12:32\u201346.","journal-title":"Curr Alzheimer Res"},{"key":"452_CR133","doi-asserted-by":"crossref","unstructured":"Horak M, Petralia RS, Kaniakova M, Sans N. ER to synapse trafficking of NMDA receptors. Front Cell Neurosci. 2014;8:394.","DOI":"10.3389\/fncel.2014.00394"},{"key":"452_CR134","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ceb.2010.04.007","volume":"22","author":"F Barr","year":"2010","unstructured":"Barr F, Lambright DG. Rab GEFs and GAPs. Curr Opin Cell Biol. 2010;22:461\u201370.","journal-title":"Curr Opin Cell Biol"},{"key":"452_CR135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/CIA.S159148","volume":"14","author":"JP Tavana","year":"2018","unstructured":"Tavana JP, Rosene M, Jensen NO, Ridge PG, Kauwe JS, Karch CM. RAB10: an Alzheimer's disease resilience locus and potential drug target. Clin Interv Aging. 2018;14:73\u20139.","journal-title":"Clin Interv Aging"},{"key":"452_CR136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/21541248.2016.1277001","volume":"9","author":"ML Mignogna","year":"2018","unstructured":"Mignogna ML, D'Adamo P. Critical importance of RAB proteins for synaptic function. Small GTPases. 2018;9:145\u201357.","journal-title":"Small GTPases"},{"key":"452_CR137","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/NEN.0b013e3181f52e01","volume":"69","author":"S Baig","year":"2010","unstructured":"Baig S, Joseph SA, Tayler H, Abraham R, Owen MJ, Williams J, et al. Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol. 2010;69:1071\u20137.","journal-title":"J Neuropathol Exp Neurol"},{"key":"452_CR138","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12035-014-8878-3","volume":"52","author":"W Xu","year":"2015","unstructured":"Xu W, Tan L, Yu J-T. The role of PICALM in Alzheimer\u2019s disease. Mol Neurobiol. 2015;52:399\u2013413.","journal-title":"Mol Neurobiol"},{"key":"452_CR139","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094\u20139.","journal-title":"Nat Genet"},{"key":"452_CR140","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088\u201393.","journal-title":"Nat Genet"},{"key":"452_CR141","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-013-1111-z","volume":"125","author":"K Ando","year":"2013","unstructured":"Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor CALM\/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathol. 2013;125:861\u201378.","journal-title":"Acta Neuropathol"},{"key":"452_CR142","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nn.4025","volume":"18","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K, et al. Central role for PICALM in amyloid-\u03b2 blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18:978\u201387.","journal-title":"Nat Neurosci"},{"key":"452_CR143","doi-asserted-by":"publisher","first-page":"e91242","DOI":"10.1371\/journal.pone.0091242","volume":"9","author":"I Parikh","year":"2014","unstructured":"Parikh I, Fardo DW, Estus S. Genetics of PICALM expression and Alzheimer's disease. PLoS One. 2014;9:e91242.","journal-title":"PLoS One"},{"key":"452_CR144","doi-asserted-by":"crossref","unstructured":"Jackson J, Jambrina E, Li J, Marston H, Menzies F, Phillips K, et al. Targeting the synapse in Alzheimer\u2019s disease. Front Neurosci. 2019;13:735.","DOI":"10.3389\/fnins.2019.00735"},{"key":"452_CR145","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41539-019-0048-y","volume":"4","author":"WC Abraham","year":"2019","unstructured":"Abraham WC, Jones OD, Glanzman DL. Is plasticity of synapses the mechanism of long-term memory storage? npj Sci Learn. 2019;4:9.","journal-title":"npj Sci Learn"},{"key":"452_CR146","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nature13163","volume":"507","author":"T Lu","year":"2014","unstructured":"Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, et al. REST and stress resistance in ageing and Alzheimer's disease. Nature. 2014;507:448\u201354.","journal-title":"Nature"},{"key":"452_CR147","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.celrep.2019.01.023","volume":"26","author":"K Meyer","year":"2019","unstructured":"Meyer K, Feldman HM, Lu T, Drake D, Lim ET, Ling KH, et al. REST and neural gene network Dysregulation in iPSC models of Alzheimer's disease. Cell Rep. 2019;26:1112\u20131127.e1119.","journal-title":"Cell Rep"},{"key":"452_CR148","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1523\/JNEUROSCI.1604-11.2011","volume":"31","author":"Z Gao","year":"2011","unstructured":"Gao Z, Ure K, Ding P, Nashaat M, Yuan L, Ma J, et al. The master negative regulator REST\/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells. J Neurosci. 2011;31:9772.","journal-title":"J Neurosci"},{"key":"452_CR149","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/mp.2017.144","volume":"22","author":"M Song","year":"2017","unstructured":"Song M, Martinowich K, Lee FS. BDNF at the synapse: why location matters. Mol Psychiatry. 2017;22:1370\u20135.","journal-title":"Mol Psychiatry"},{"key":"452_CR150","doi-asserted-by":"publisher","first-page":"10458","DOI":"10.1073\/pnas.0401827101","volume":"101","author":"AW Bruce","year":"2004","unstructured":"Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, Chapman M, et al. Genome-wide analysis of repressor element 1 silencing transcription factor\/neuron-restrictive silencing factor (REST\/NRSF) target genes. Proc Natl Acad Sci U S A. 2004;101:10458.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"452_CR151","doi-asserted-by":"crossref","unstructured":"Cunha C, Brambilla R, Thomas K. A simple role for BDNF in learning and memory? Front Mol Neurosci. 2010;3:1.","DOI":"10.3389\/neuro.02.001.2010"},{"key":"452_CR152","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/ijms20020257","volume":"20","author":"TKS Ng","year":"2019","unstructured":"Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC-M. Decreased serum brain-derived Neurotrophic factor (BDNF) levels in patients with Alzheimer's disease (AD): a systematic review and meta-analysis. Int J Mol Sci. 2019;20:257.","journal-title":"Int J Mol Sci"},{"key":"452_CR153","first-page":"2441","volume":"39","author":"B de Pins","year":"2019","unstructured":"de Pins B, Cifuentes-D\u00edaz C, Farah AT, L\u00f3pez-Molina L, Montalban E, Sancho-Balsells A, et al. Conditional BDNF delivery from astrocytes rescues memory deficits, spine density, and synaptic properties in the 5xFAD mouse model of Alzheimer disease. J Neurosci. 2019;39:2441.","journal-title":"J Neurosci"},{"key":"452_CR154","doi-asserted-by":"publisher","first-page":"27358","DOI":"10.1038\/srep27358","volume":"6","author":"CC Wu","year":"2016","unstructured":"Wu CC, Lien CC, Hou WH, Chiang PM, Tsai KJ. Gain of BDNF function in engrafted neural stem cells promotes the therapeutic potential for Alzheimer's disease. Sci Rep. 2016;6:27358.","journal-title":"Sci Rep"},{"key":"452_CR155","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci. 2010;30:14708\u201318.","journal-title":"J Neurosci"},{"key":"452_CR156","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.mp.4000952","volume":"7","author":"M Ventriglia","year":"2002","unstructured":"Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, et al. Association between the BDNF 196 a\/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry. 2002;7:136\u20137.","journal-title":"Mol Psychiatry"},{"key":"452_CR157","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1093\/brain\/aww201","volume":"139","author":"E Rogaeva","year":"2016","unstructured":"Rogaeva E, Schmitt-Ulms G. Does BDNF Val66Met contribute to preclinical Alzheimer\u2019s disease? Brain. 2016;139:2586\u20139.","journal-title":"Brain"},{"key":"452_CR158","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/brain\/aww200","volume":"139","author":"YY Lim","year":"2016","unstructured":"Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TLS, et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain. 2016;139:2766\u201377.","journal-title":"Brain"},{"key":"452_CR159","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.25299","volume":"84","author":"YY Lim","year":"2018","unstructured":"Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, et al. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Ann Neurol. 2018;84:424\u201335.","journal-title":"Ann Neurol"},{"key":"452_CR160","doi-asserted-by":"publisher","first-page":"e86498","DOI":"10.1371\/journal.pone.0086498","volume":"9","author":"YY Lim","year":"2014","unstructured":"Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. PLoS One. 2014;9:e86498.","journal-title":"PLoS One"},{"key":"452_CR161","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","volume":"112","author":"MF Egan","year":"2003","unstructured":"Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257\u201369.","journal-title":"Cell"},{"key":"452_CR162","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13041-017-0324-9","volume":"10","author":"AH Rasmussen","year":"2017","unstructured":"Rasmussen AH, Rasmussen HB, Silahtaroglu A. The DLGAP family: neuronal expression, function and role in brain disorders. Mol Brain. 2017;10:43.","journal-title":"Mol Brain"},{"key":"452_CR163","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JAD-142106","volume":"44","author":"M Chaudhry","year":"2015","unstructured":"Chaudhry M, Wang X, Bamne MN, Hasnain S, Demirci FY, Lopez OL, et al. Genetic variation in imprinted genes is associated with risk of late-onset Alzheimer's disease. J Alzheimers Dis. 2015;44:989\u201394.","journal-title":"J Alzheimers Dis"},{"key":"452_CR164","unstructured":"DLGAP1. Accessed 5 March 2021. https:\/\/agora.ampadportal.org\/genes\/(genes-router:gene-details\/ENSG00000170579). Accessed 5 Mar 2021."},{"key":"452_CR165","doi-asserted-by":"publisher","first-page":"e23097","DOI":"10.1371\/journal.pone.0023097","volume":"6","author":"F Roselli","year":"2011","unstructured":"Roselli F, Livrea P, Almeida OFX. CDK5 is essential for soluble amyloid \u03b2-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton. PLoS One. 2011;6:e23097.","journal-title":"PLoS One"},{"key":"452_CR166","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:575\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"key":"452_CR167","doi-asserted-by":"crossref","unstructured":"Tsai AP, Dong C, Preuss C, Moutinho M, Lin PB-C, Hajicek N, et al. PLCG2 as a risk factor for Alzheimer\u2019s disease. bioRxiv. 2020:2020.2005.2019.104216.","DOI":"10.21203\/rs.3.rs-38216\/v1"},{"key":"452_CR168","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","volume":"12","author":"AG Efthymiou","year":"2017","unstructured":"Efthymiou AG, Goate AM. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.","journal-title":"Mol Neurodegener"},{"key":"452_CR169","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429\u201335.","journal-title":"Nat Genet"},{"key":"452_CR170","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-019-0469-0","volume":"11","author":"L Magno","year":"2019","unstructured":"Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, et al. Alzheimer\u2019s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11:16.","journal-title":"Alzheimers Res Ther"},{"key":"452_CR171","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00401-019-02026-8","volume":"138","author":"SJ van der Lee","year":"2019","unstructured":"van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer\u2019s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2019;138:237\u201350.","journal-title":"Acta Neuropathol"},{"key":"452_CR172","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.tibs.2014.09.004","volume":"39","author":"H Koss","year":"2014","unstructured":"Koss H, Bunney TD, Behjati S, Katan M. Dysfunction of phospholipase C\u03b3 in immune disorders and cancer. Trends Biochem Sci. 2014;39:603\u201311.","journal-title":"Trends Biochem Sci"},{"key":"452_CR173","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2012","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2012;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"452_CR174","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2005.01.018","volume":"22","author":"P Yu","year":"2005","unstructured":"Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD, et al. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C&#x3b3;2 that specifically increases external Ca<sup>2+<\/sup> entry. Immunity. 2005;22:451\u201365.","journal-title":"Immunity"},{"key":"452_CR175","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.neurobiolaging.2016.03.004","volume":"42","author":"H Zheng","year":"2016","unstructured":"Zheng H, Liu C-C, Atagi Y, Chen X-F, Jia L, Yang L, et al. Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation. Neurobiol Aging. 2016;42:132\u201341.","journal-title":"Neurobiol Aging"},{"key":"452_CR176","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2009.01.009","volume":"21","author":"JW Ford","year":"2009","unstructured":"Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009;21:38\u201346.","journal-title":"Curr Opin Immunol"},{"key":"452_CR177","doi-asserted-by":"crossref","unstructured":"Song Y-N, Li J-Q, Tan C-C, Wang H-F, Tan M-S, Cao X-P, et al. tAsDNI: TREML2 mutation mediate Alzheimer\u2019s disease risk by altering neuronal degeneration. Front Neurosci. 2019;13:455.","DOI":"10.3389\/fnins.2019.00455"},{"key":"452_CR178","first-page":"21","volume":"41","author":"C Laurent","year":"2018","unstructured":"Laurent C, Bu\u00e9e L, Blum D. Tau and neuroinflammation: what impact for Alzheimer's disease and Tauopathies? Biom J. 2018;41:21\u201333.","journal-title":"Biom J"},{"key":"452_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050976","volume":"7","author":"CM Karch","year":"2012","unstructured":"Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One. 2012;7:e50976.","journal-title":"PLoS One"},{"key":"452_CR180","doi-asserted-by":"publisher","first-page":"eaau2291","DOI":"10.1126\/scitranslmed.aau2291","volume":"11","author":"Y Deming","year":"2019","unstructured":"Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Sci Transl Med. 2019;11:eaau2291.","journal-title":"Sci Transl Med"},{"key":"452_CR181","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/alzrt247","volume":"6","author":"J-i Satoh","year":"2014","unstructured":"Satoh J-i, Kino Y, Kawana N, Yamamoto Y, Ishida T, Saito Y, et al. TMEM106B expression is reduced in Alzheimer\u2019s disease brains. Alzheimers Res Ther. 2014;6:17.","journal-title":"Alzheimers Res Ther"},{"key":"452_CR182","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1212\/WNL.0b013e31820a0e3b","volume":"76","author":"N Finch","year":"2011","unstructured":"Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76:467\u201374.","journal-title":"Neurology"},{"key":"452_CR183","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cels.2017.02.009","volume":"4","author":"H Rhinn","year":"2017","unstructured":"Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst. 2017;4:404\u2013415.e405.","journal-title":"Cell Syst"},{"key":"452_CR184","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.neuron.2017.06.026","volume":"95","author":"ZA Klein","year":"2017","unstructured":"Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, et al. Loss of TMEM106B ameliorates Lysosomal and Frontotemporal dementia-related phenotypes in Progranulin-deficient mice. Neuron. 2017;95:281\u2013296.e286.","journal-title":"Neuron"},{"key":"452_CR185","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13024-018-0268-2","volume":"13","author":"Y Ren","year":"2018","unstructured":"Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X, et al. TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener. 2018;13:35.","journal-title":"Mol Neurodegener"},{"key":"452_CR186","volume":"6","author":"J Cummings","year":"2020","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement Transl Res Clin Interv. 2020;6:e12050.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"452_CR187","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/clpt.2014.147","volume":"96","author":"BM Bettcher","year":"2014","unstructured":"Bettcher BM, Kramer JH. Longitudinal inflammation, cognitive decline, and Alzheimer's disease: a mini-review. Clin Pharmacol Ther. 2014;96:464\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"452_CR188","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"452_CR189","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1093\/brain\/awaa209","volume":"143","author":"L Dumitrescu","year":"2020","unstructured":"Dumitrescu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelman CD, et al. Genetic variants and functional pathways associated with resilience to Alzheimer's disease. Brain. 2020;143:2561\u201375.","journal-title":"Brain"},{"key":"452_CR190","doi-asserted-by":"crossref","unstructured":"Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D, et al. Exome sequencing identifies novel AD-associated genes. Alzheimers Dement.\u00a02020;16:e04159.","DOI":"10.1002\/alz.041592"},{"key":"452_CR191","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41588-018-0147-3","volume":"50","author":"JJ Lee","year":"2018","unstructured":"Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50:1112\u201321.","journal-title":"Nat Genet"},{"key":"452_CR192","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/mp.2009.55","volume":"15","author":"CMA Haworth","year":"2010","unstructured":"Haworth CMA, Wright MJ, Luciano M, Martin NG, de Geus EJC, van Beijsterveldt CEM, et al. The heritability of general cognitive ability increases linearly from childhood to young adulthood. Mol Psychiatry. 2010;15:1112\u201320.","journal-title":"Mol Psychiatry"},{"key":"452_CR193","doi-asserted-by":"publisher","first-page":"e0196597","DOI":"10.1371\/journal.pone.0196597","volume":"13","author":"M Spengler","year":"2018","unstructured":"Spengler M, Gottschling J, Hahn E, Tucker-Drob EM, Harzer C, Spinath FM. Does the heritability of cognitive abilities vary as a function of parental education? Evidence from a German twin sample. PLoS One. 2018;13:e0196597.","journal-title":"PLoS One"},{"key":"452_CR194","doi-asserted-by":"crossref","unstructured":"Morris TT, Davies NM, Dorling D, Richmond RC, Smith GD. Examining the genetic influences of educational attainment and the validity of value-added measures of progress. bioRxiv. 2018:233635.","DOI":"10.1101\/233635"},{"key":"452_CR195","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1177\/0956797613493292","volume":"24","author":"KJ Kan","year":"2013","unstructured":"Kan KJ, Wicherts JM, Dolan CV, van der Maas HL. On the nature and nurture of intelligence and specific cognitive abilities: the more heritable, the more culture dependent. Psychol Sci. 2013;24:2420\u20138.","journal-title":"Psychol Sci"},{"key":"452_CR196","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0963721413485087","volume":"22","author":"EM Tucker-Drob","year":"2013","unstructured":"Tucker-Drob EM, Briley DA, Harden KP. Genetic and environmental influences on cognition across development and context. Curr Dir Psychol Sci. 2013;22:349\u201355.","journal-title":"Curr Dir Psychol Sci"},{"key":"452_CR197","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.1996.03530310034029","volume":"275","author":"DA Snowdon","year":"1996","unstructured":"Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings From the Nun study. JAMA. 1996;275:528\u201332.","journal-title":"JAMA"},{"key":"452_CR198","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2020.1941","volume":"77","author":"S Oveisgharan","year":"2020","unstructured":"Oveisgharan S, Wilson RS, Yu L, Schneider JA, Bennett DA. Association of Early-Life Cognitive Enrichment with Alzheimer Disease Pathological Changes and Cognitive Decline. JAMA Neurol. 2020;77:1217\u201324.","journal-title":"JAMA Neurol"},{"key":"452_CR199","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/jamaneurol.2020.1114","volume":"77","author":"TJ Hohman","year":"2020","unstructured":"Hohman TJ, Kaczorowski CC. Modifiable lifestyle factors in Alzheimer disease: an opportunity to transform the therapeutic landscape through Transdisciplinary collaboration. JAMA Neurol. 2020;77:1207\u20139.","journal-title":"JAMA Neurol"},{"key":"452_CR200","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/gerona\/gly174","volume":"74","author":"P Sebastiani","year":"2019","unstructured":"Sebastiani P, Gurinovich A, Nygaard M, Sasaki T, Sweigart B, Bae H, et al. APOE alleles and extreme human longevity. J Gerontol A. 2019;74:44\u201351.","journal-title":"J Gerontol A"},{"key":"452_CR201","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mad.2016.02.010","volume":"155","author":"S Ryu","year":"2016","unstructured":"Ryu S, Atzmon G, Barzilai N, Raghavachari N, Suh Y. Genetic landscape of APOE in human longevity revealed by high-throughput sequencing. Mech Ageing Dev. 2016;155:7\u20139.","journal-title":"Mech Ageing Dev"},{"key":"452_CR202","doi-asserted-by":"publisher","first-page":"15122","DOI":"10.1073\/pnas.1902452116","volume":"116","author":"K Whittemore","year":"2019","unstructured":"Whittemore K, Vera E, Mart\u00ednez-Nevado E, Sanpera C, Blasco MA. Telomere shortening rate predicts species life span. Proc Natl Acad Sci. 2019;116:15122.","journal-title":"Proc Natl Acad Sci"},{"key":"452_CR203","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.trci.2019.11.003","volume":"5","author":"ER Mahoney","year":"2019","unstructured":"Mahoney ER, Dumitrescu L, Seto M, Nudelman KNH, Buckley RF, Gifford KA, et al. Telomere length associations with cognition depend on Alzheimer's disease biomarkers. Alzheimers Dement (N Y). 2019;5:883\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"key":"452_CR204","doi-asserted-by":"crossref","first-page":"174550651881799","DOI":"10.1177\/1745506518817995","volume":"14","author":"MK Andrew","year":"2018","unstructured":"Andrew MK, Tierney MC. The puzzle of sex, gender and Alzheimer\u2019s disease: why are women more often affected than men? Womens Health (Lond). 2018;14:1745506518817995.","journal-title":"Womens Health (Lond)"},{"key":"452_CR205","doi-asserted-by":"crossref","unstructured":"Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74:1178\u201389.","DOI":"10.1001\/jamaneurol.2017.2188"},{"key":"452_CR206","doi-asserted-by":"crossref","unstructured":"Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham GW, Kunkle B, et al. Sex-specific effects of Apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75:989\u201398.","DOI":"10.1001\/jamaneurol.2018.0821"},{"key":"452_CR207","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11682-016-9523-8","volume":"11","author":"MEI Koran","year":"2017","unstructured":"Koran MEI, Wagener M, Hohman TJ, Alzheimer\u2019s Neuroimaging I. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11:205\u201313.","journal-title":"Brain Imaging Behav"},{"key":"452_CR208","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archpsyc.62.6.685","volume":"62","author":"LL Barnes","year":"2005","unstructured":"Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62:685\u201391.","journal-title":"Arch Gen Psychiatry"},{"key":"452_CR209","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","volume":"76","author":"RF Buckley","year":"2019","unstructured":"Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex differences in the Association of Global Amyloid and Regional tau Deposition Measured by positron emission tomography in clinically Normal older adults. JAMA Neurol. 2019;76:542\u201351.","journal-title":"JAMA Neurol"},{"key":"452_CR210","doi-asserted-by":"crossref","unstructured":"Buckley RF, Scott MR, Jacobs HIL, Schultz AP, Properzi MJ, Amariglio RE, et al. Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol. 2020;88:921\u201332.","DOI":"10.1002\/ana.25878"},{"key":"452_CR211","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00401-018-1881-4","volume":"136","author":"Y Deming","year":"2018","unstructured":"Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, et al. Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol. 2018;136:857\u201372.","journal-title":"Acta Neuropathol"},{"key":"452_CR212","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/brain\/awz206","volume":"142","author":"L Dumitrescu","year":"2019","unstructured":"Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Bush WS, et al. Sex differences in the genetic predictors of Alzheimer\u2019s pathology. Brain. 2019;142:2581\u20139.","journal-title":"Brain"},{"key":"452_CR213","doi-asserted-by":"crossref","unstructured":"Dumitrescu L, Mayeda ER, Sharman K, Moore AM, Hohman TJ. Sex differences in the genetic architecture of Alzheimer\u2019s disease. Curr Genet Med Rep. 2019;7:13\u201321.","DOI":"10.1007\/s40142-019-0157-1"},{"key":"452_CR214","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019;570:332\u20137.","journal-title":"Nature"},{"key":"452_CR215","first-page":"261","volume-title":"Handbook of clinical neurology","author":"DB Dubal","year":"2020","unstructured":"Dubal DB. Chapter 16 - sex difference in Alzheimer\u2019s disease: an updated, balanced and emerging perspective on differing vulnerabilities. In: Lanzenberger R, Kranz GS, Savic I, editors. Handbook of clinical neurology, vol. 175. Cambridge: Elsevier; 2020. p. 261\u201373."}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-021-00452-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T07:13:16Z","timestamp":1706166796000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-021-00452-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":215,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1186\/s13024-021-00452-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors, MS, RW, LD, and TH have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}